Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2021-05-10 Regulatory Filings
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
NanoRepro AG: Neuartiger Antikorper-Test eroffnet zusatzliches hohes Potenzial
Regulatory Filings Classification · 100% confidence The document is a press release dated May 10, 2021, originating from NanoRepro AG, distributed via DGAP-News. It announces product development (a new antibody test for post-vaccination immunity) and strategic business expansion plans. It is not a formal regulatory filing like a 10-K, nor is it a transcript (CT) or a formal dividend notice (DIV). It is an announcement of operational news and strategic direction, which fits best under the general category of corporate news releases. Since it is not a formal financial report (like IR or 10-K) but rather an announcement of business updates, it is classified as a Regulatory Filing (RNS) as the most appropriate general category for non-standard, time-sensitive corporate news distributed via official channels (DGAP). It is too detailed to be a simple Report Publication Announcement (RPA) which usually just points to another document.
2021-05-10 German
NanoRepro AG: Vertrag mit CEO Lisa Jungst wird vorzeitig verlangert
Board/Management Information Classification · 100% confidence The document is a news release from NanoRepro AG, dated May 4, 2021, announcing the early extension of the contract for CEO Lisa Jüngst for three years. The key subject is a change in senior management tenure. This directly aligns with the definition for Board/Management Information (MANG), which covers announcements of changes in senior management.
2021-05-04 German
NanoRepro AG: Hochqualitative Corona-Schnelltests treiben Umsatzwachstum
Earnings Release Classification · 98% confidence The document is a press release dated April 1, 2021, titled "NanoRepro AG: Hochqualitative Corona-Schnelltests treiben Umsatzwachstum" (High-quality Corona rapid tests drive revenue growth). It discusses recent sales volumes, confirms an exclusive partnership, and provides a revenue forecast for 2021 (between 250 and 400 million EUR). This content—announcing key financial highlights, performance drivers, and future outlook for a specific period (the year 2021)—is characteristic of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), nor is it merely an announcement of a report (RPA). Q1 2021
2021-04-01 German
NanoRepro AG: Konkretisierung Prognose 2021
Management Reports Classification · 99% confidence The document is an 'Ad-hoc' announcement dated March 30, 2021, titled 'NanoRepro AG: Konkretisierung Prognose 2021' (Specification of Forecast 2021). It explicitly states the expected revenue and EBITDA figures for the fiscal year 2021, which is a forward-looking statement regarding financial performance. This fits the definition of an Earnings Release (ER) as it is an initial announcement of financial expectations/results for a period, even if it's a forecast update rather than final audited results. It is not a full 10-K, a transcript (CT), or a management discussion (MDA), but rather a concise release of key financial figures/projections. Given the context of providing specific financial guidance/forecasts, ER is the most appropriate code.
2021-03-30 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2019 bis zum 31.12.2019
Audit Report / Information Classification · 95% confidence The document is a German 'Jahresabschluss' (Annual Financial Statement) for Oehmichen Optik AG for the fiscal year 2019. It contains a balance sheet (Bilanz), notes (Anhang), and details regarding accounting methods, which are standard components of a full annual financial report. While it is not a consolidated 10-K (as it is a German AG filing), it serves the equivalent function of an annual financial report for the entity. Therefore, it is classified as an Annual Report. FY 2019
2021-03-19 German
NanoRepro AG: Barkapitalerhohung mit Bezugsrechtsausschluss deutlich uberzeichnet
Share Issue/Capital Change Classification · 99% confidence The document is a news release from NanoRepro AG dated March 17, 2021, announcing that a planned capital increase ('Barkapitalerhöhung') with exclusion of subscription rights has been fully placed with institutional investors and was significantly oversubscribed. It details the increase in share capital, the placement price, and the intended use of the net proceeds (working capital, financing production of COVID-19 tests). This content directly relates to fundraising, financing activities, and capital structure changes. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it is a news release, the core subject matter is the capital action itself, making CAP more specific than the general 'RPA' or 'RNS' fallback.
2021-03-17 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.